A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer.
Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
- IRB Number: 1811442903 (S1706)
- Research Study Identifier: TX10166
- Principal Investigator: Richard Zellars, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required